AxoGen Inc., an Alachua, Fla.-based commercializer of peripheral nerve regeneration technologies, has raised $12.1 million in Series C funding. Backers include Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures and Springboard Capital. Get more info.
AxoGen, Inc., which is commercializing innovative peripheral nerve regeneration technologies, achieves another milestone by raising $12.1 million in Series C funding from Accuitive Medical Ventures, Cardinal Partners, De Novo Ventures and Springboard Capital II.
In July 2007, AxoGen established itself in the nerve regeneration field with the launch of AVANCE Nerve Graft for peripheral nerve repair. AVANCE Nerve Graft is a human allograft nerve that is minimally processed to preserve the three dimensional structure of the nerve basal lamina and the inherent growth promoters that lie within. This process decellularizes the graft